Impact of ADAM17 Expression as a Potential Prognostic Biomarker and Target for Therapy in Node-negative Breast Carcinoma

References (130)

1. 1 Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [DOI]
2. 2 Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer [DOI]
3. 3 The ADAM metalloproteinases [DOI]
4. 4 Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. [DOI]
5. 5 ADAMs in cancer cell proliferation and progression [DOI]
6. 6 Use of Statistics to Assess the Global Burden of Breast Cancer [DOI]
7. 7 Tamoxifen and Breast Density in Women at Increased Risk of Breast Cancer [DOI]
8. 8 Metalloproteinases and their inhibitors in tumor angiogenesis [DOI]
9. 9 Emerging roles of ADAM and ADAMTS metalloproteinases in cancer [DOI]
10. 10 Changes in Breast Density Associated With Initiation, Discontinuation, and Continuing Use of Hormone Replacement Therapy [DOI]
11. 11 ADAM 12 Cleaves Extracellular Matrix Proteins and Correlates with Cancer Status and Stage [DOI]
12. 12 Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C‐shaped scaffold [DOI]
13. 13 The Ectodomain Shedding of E-cadherin by ADAM15 Supports ErbB Receptor Activation [DOI]
14. 14 Diet, Body Size, and Breast Cancer [DOI]
15. 15 Well-Done Meat Intake and the Risk of Breast Cancer [DOI]
16. 16 Increased expression of ADAM family members in human breast cancer and breast cancer cell lines [DOI]
17. 17 Metalloproteinase Disintegrins ADAM8 and ADAM19 Are Highly Regulated in Human Primary Brain Tumors and their Expression Levels and Activities Are Associated with Invasiveness [DOI]
18. 18 Expression of ADAM‐9 mRNA and protein in human breast cancer [DOI]
19. 19 ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma [DOI]
20. 20 Overexpression of ADAM9 in Non-Small Cell Lung Cancer Correlates with Brain Metastasis [DOI]
21. 21 Ectodomain shedding of the EGF‐receptor ligand epigen is mediated by ADAM17 [DOI]
22. 22 ADAMs, cell migration and cancer [DOI]
23. 23 Functional Characteristic of Snake Venom Disintegrins: Potential Therapeutic Implication [DOI]
24. 24 Radiation and Other Environmental Exposures and Breast Cancer [DOI]
25. 25 ADAM17 Regulates Epidermal Growth Factor Receptor Expression through the Activation of Notch1 in Non–Small Cell Lung Cancer [DOI]
26. 26 Inhibition of ADAM17 reduces hypoxia‐induced brain tumor cell invasiveness [DOI]
27. 27 ADAM10 Is the Constitutive Functional Sheddase of CD44 in Human Melanoma Cells [DOI]
28. 28 Metalloproteinase-like, disintegrin-like, cysteine-rich proteins MDC2 and MDC3: novel human cellular disintegrins highly expressed in the brain [DOI]
29. 29 ADAM10 Is Upregulated in Melanoma Metastasis Compared with Primary Melanoma [DOI]
30. 30 Loss of PTEN is associated with progression to androgen independence [DOI]
31. 31 The role of ADAMs in disease pathophysiology [DOI]
32. 32 UV‐induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines [DOI]
33. 33 Breast Cancer: A Neglected Disease for the Majority of Affected Women Worldwide [DOI]
34. 34 An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer [DOI]
35. 35 ADAM28 is a serological and histochemical marker for non‐small‐cell lung cancers [DOI]
36. 36 Interaction of the Metalloprotease Disintegrins MDC9 and MDC15 with Two SH3 Domain-containing Proteins, Endophilin I and SH3PX1 [DOI]
37. 37 ADAM 12 Protease Induces Adipogenesis in Transgenic Mice [DOI]
38. 38 Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response [DOI]
39. 39 The expression of the ADAMs proteases in prostate cancer cell lines and their regulation by dihydrotestosterone [DOI]
40. 40 Isolation of Two Novel Metalloproteinase-Disintegrin (ADAM) cDNAs That Show Testis-Specific Gene Expression [DOI]
41. 41 Reactive oxygen species mediate androgen receptor‐ and serum starvation‐elicited downstream signaling of ADAM9 expression in human prostate cancer cells [DOI]
42. 42 The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition [DOI]
43. 43 ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers [DOI]
44. 44 Helicobacter pylori-Stimulated Interleukin-8 (IL-8) Promotes Cell Proliferation Through Transactivation of Epidermal Growth Factor Receptor (EGFR) by Disintegrin and Metalloproteinase (ADAM) Activation [DOI]
45. 45 Genetic variants of CYP19 (aromatase) and breast cancer risk [DOI]
46. 46 Prognostic value of ADAM17 in human gastric cancer [DOI]
47. 47 A novel metalloprotease/disintegrin–like gene at 17q21.3 is somatically rearranged in two primary breast cancers [DOI]
48. 48 Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen [DOI]
49. 49 Variation in lung cancer survival rates between countries: Do differences in data reporting contribute? [DOI]
50. 50 Hormone replacement therapy and biological aggressiveness of breast cancer [DOI]
51. 51 Cancer treatment and survivorship statistics, 2012 [DOI]
52. 52 Signalling pathways of the TNF superfamily: a double-edged sword [DOI]
53. 53 The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor [DOI]
54. 54 Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 [DOI]
55. 55 Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands [DOI]
56. 56 Atypical hyperplastic lesions of the female breast. A long-term follow-up study [DOI]
57. 57 World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs [DOI]
58. 58 The antiestrogenic effect of cigarette smoking in women [DOI]
59. 59 Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma [DOI]
60. 60 Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers [DOI]
61. 61 The in vitro activity of ADAM‐10 is inhibited by TIMP‐1 and TIMP‐3 [DOI]
62. 62 Effects of Alcohol Consumption on Plasma and Urinary Hormone Concentrations in Premenopausal Women [DOI]
63. 63 Mechanism and biological significance of CD44 cleavage [DOI]
64. 64 Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer [DOI]
65. 65 Substrate Selectivity of Epidermal Growth Factor-Receptor Ligand Sheddases and their Regulation by Phorbol Esters and Calcium Influx [DOI]
66. 66 Role of ADAMs in Cancer Formation and Progression [DOI]
67. 67 Direct Activation of TACE-Mediated Ectodomain Shedding by p38 MAP Kinase Regulates EGF Receptor-Dependent Cell Proliferation [DOI]
68. 68 Targeting TACE-dependent EGFR ligand shedding in breast cancer [DOI]
69. 69 Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older.
70. 70 CD44 is the Principal Mediator of Hyaluronic-Acid-Induced Melanoma Cell Proliferation [DOI]
71. 71 ADAM17 as a Therapeutic Target in Multiple Diseases [DOI]
72. 72 Distinct ADAM Metalloproteinases Regulate G Protein-coupled Receptor-induced Cell Proliferation and Survival [DOI]
73. 73 The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer [DOI]
74. 74 Molecular Pathology of Breast Cancer [DOI]
75. 75 Stromelysin‐1: Three‐dimensional structure of the inhibited catalytic domain and of the C‐truncated proenzyme [DOI]
76. 76 ADAM 12, a Disintegrin Metalloprotease, Interacts with Insulin-like Growth Factor-binding Protein-3 [DOI]
77. 77 TACE and other ADAM proteases as targets for drug discovery [DOI]
78. 78 Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer [DOI]
79. 79 Up‐regulated expression of ADAM17 in human colon carcinoma: co‐expression with EGFR in neoplastic and endothelial cells [DOI]
80. 80 Breaking up the tie: Disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion [DOI]
81. 81 ADAM28 Is Overexpressed in Human Breast Carcinomas: Implications for Carcinoma Cell Proliferation through Cleavage of Insulin-like Growth Factor Binding Protein-3 [DOI]
82. 82 Molecular Profiling of ADAM12 in Human Bladder Cancer [DOI]
83. 83 Therapeutic Benefits from Targeting of ADAM Family Members [DOI]
84. 84 ADAM15 Disintegrin Is Associated with Aggressive Prostate and Breast Cancer Disease [DOI]
85. 85 ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression [DOI]
86. 86 Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma [DOI]
87. 87 Oxidative Stress Induces ADAM9 Protein Expression in Human Prostate Cancer Cells [DOI]
88. 88 ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation [DOI]
89. 89 ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer [DOI]
90. 90 ADAM-17 predicts adverse outcome in patients with breast cancer [DOI]
91. 91 ADAM9 Expression is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer [DOI]
92. 92 EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments [DOI]
93. 93 ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis [DOI]
94. 94 Adam‐9 expression and regulation in human skin melanoma and melanoma cell lines [DOI]
95. 95 ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway [DOI]
96. 96 Expression of ADAM15 in lung carcinomas [DOI]
97. 97 Targeting ADAMS and ERBBs in lung cancer [DOI]
98. 98 Structure-Activity Relationship Studies on ADAM Protein-Integrin Interactions [DOI]
99. 99 The disintegrin‐metalloproteinases ADAM 10, 12 and 17 are upregulated in invading peripheral tumor cells of basal cell carcinomas [DOI]
100. 100 Flat Epithelial Atypia of the Breast [DOI]
101. 101 SEER Cancer Statistics Review, 1975-2003
102. 102 Cancer Incidence in Five Continents [DOI]
103. 103 Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study [DOI]
104. 104 Global cancer statistics [DOI]
105. 105 Quantitative Classification of Mammographic Densities and Breast Cancer Risk: Results From the Canadian National Breast Screening Study [DOI]
106. 106 The rising burden of cancer in the developing world [DOI]
107. 107 Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial [DOI]
108. 108 Serum Tumor Markers in Breast Cancer: Are They of Clinical Value? [DOI]
109. 109 ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors [DOI]
110. 110 A longitudinal study of the effects of menopause on mammographic features.
111. 111 The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? [DOI]
112. 112 Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis [DOI]
113. 113 A Secreted Form of ADAM9 Promotes Carcinoma Invasion through Tumor-Stromal Interactions [DOI]
114. 114 Predictive Markers in Breast and Other Cancers: A Review [DOI]
115. 115 A Role for ADAM12 in Breast Tumor Progression and Stromal Cell Apoptosis [DOI]
116. 116 Pathological Neovascularization Is Reduced by Inactivation of ADAM17 in Endothelial Cells but Not in Pericytes [DOI]
117. 117 Synergistic Inhibition with a Dual Epidermal Growth Factor Receptor/HER-2/neu Tyrosine Kinase Inhibitor and a Disintegrin and Metalloprotease Inhibitor [DOI]
118. 118 TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer [DOI]
119. 119 Evidence of Antiangiogenic and Antimetastatic Activities of the Recombinant Disintegrin Domain of Metargidin [DOI]
120. 120 ADAM9 Is Involved in Pathological Retinal Neovascularization [DOI]
121. 121 Handbook of proteolytic enzymes, 3rd Edition
122. 122 Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA.
123. 123 How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study [DOI]
124. 124 Targeting the epidermal growth factor receptor: a clinical reality.
125. 125 Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer.
126. 126 Antioxidants and Breast Cancer [DOI]
127. 127 A New Look at Node-Negative Breast Cancer [DOI]
128. 128 Anti–Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today? [DOI]
129. 129 Alcohol and breast cancer risk: the alcoholism paradox [DOI]
130. 130 “Intrinsic Gene Expression” subtypes correlated with grade and morphometric parameters reveal a high proportion of aggressive basal-like tumors among black women of African ancestry [DOI]

Cited by 0

No indexed citations yet.

Related research

• Invasive Urothelial Carcinoma of the Ureter with Associated Obstructive Uropathy and Chronic Pyelonephritis: A Case Report and Literature Review — shares topic coverage
• Rare Presentation of Metastatic Papillary Thyroid Carcinoma with Cribiform Type in Pelvic Bones — shares topic coverage
• Fecal and Salivary Microbial Gene Markers for the Non-invasive Detection of Colorectal Cancer Progression — shares topic coverage
• Synchronous Granulosa Cell Tumor of the Ovary and Urothelial Carcinoma of the Urinary Bladder: A Rare Case Report — shares topic coverage
• Multiple Bilateral Parenchymal Cavitary Lung Lesions: A Case Report — shares topic coverage